Compare IART & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | REPL |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.8M | 692.8M |
| IPO Year | 1996 | 2018 |
| Metric | IART | REPL |
|---|---|---|
| Price | $10.04 | $2.40 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $14.33 | $5.67 |
| AVG Volume (30 Days) | 689.1K | ★ 9.8M |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.70 | $1.50 |
| 52 Week High | $17.04 | $13.24 |
| Indicator | IART | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 33.50 |
| Support Level | $8.79 | $1.50 |
| Resistance Level | $11.57 | $8.83 |
| Average True Range (ATR) | 0.56 | 0.45 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 22.19 | 17.96 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.